The market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.4% from 2025 to 2035, increasing from USD 18466.9 Million in 2025 to USD 34340.7 Million by 2035.

There are subtle but significant differences in the morphology and biochemistry of the eye between men and women. These differences may affect disease susceptibility, symptoms and progression, ...

Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and obesity. Also known as GLP-1 agonists, these drugs work by mimicking a ...

When it comes to sun protection, most of us diligently apply sunscreen, wear full-sleeved clothing, and choose wide-brimmed ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA Background: Recent information suggests that the Age-Related ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

The Department of Ophthalmology at the University of Colorado Anschutz Medical Campus received a $40 million gift to enhance research into treatment of eye diseases.  The school will use the gift to ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on ...